IMM-H014 Sustained-Release Tablets With Hydrophilic Gel Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for non-alcoholic fatty liver disease, hepatitis, and drug-induced liver disease are not effective in maintaining consistent drug levels in the body, leading to poor patient compliance and potential side effects due to frequent dosing.
Innovation Solution
Development of IMM-H014 sustained-release tablets using a biphenyl compound as the active pharmaceutical ingredient, combined with hydrophilic gel skeleton materials like hydroxypropyl methylcellulose, to achieve controlled release and prolonged therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If IMM-H014 is administered orally with short half-life, then rapid absorption and high bioavailability are achieved, but frequent dosing is required which reduces patient compliance
Solution Approach 1:
The patent divides the drug release into multiple segments over time using a matrix tablet structure with hydrophilic gel skeleton. The tablet matrix segments the drug release process, allowing controlled release over extended periods (e.g., 12-24 hours), thereby reducing dosing frequency and improving patient compliance while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent employs dynamic release characteristics by using hydrophilic gel materials that undergo sol-gel transition and swelling in the gastrointestinal tract. The gel skeleton dynamically adjusts its porosity and mesh structure based on solvent penetration, controlling drug diffusion rates adaptively to maintain therapeutic levels over time while reducing dosing frequency.
2Reliability
If frequent dosing is used to maintain therapeutic levels, then consistent drug effect is achieved, but side effects increase and patient compliance decreases
Solution Approach 1:
The patent ensures continuous therapeutic action by designing a sustained-release matrix that maintains drug release over extended periods. The hydrophilic gel skeleton continuously diffuses the drug through its porous structure, preventing therapeutic troughs between doses and eliminating the need for frequent dosing, thereby reducing side effects associated with multiple administrations while maintaining consistent therapeutic effect.
Solution Approach 2:
The patent changes the release rate parameter by incorporating hydrophilic gel materials with specific viscosity and porosity characteristics. These parameter changes in the tablet matrix (controlled by gel concentration, molecular weight, and crosslinking) enable extended release duration, allowing once-daily or less frequent dosing that reduces cumulative side effects while maintaining therapeutic consistency.
3Ease of operation
If sustained-release formulation is developed, then dosing frequency is reduced and compliance improves, but manufacturing complexity increases
Solution Approach 1:
The patent applies local quality by using hydrophilic gel materials with specific rheological properties (viscosity, gel fraction, molecular weight) positioned strategically within the tablet matrix. Different regions of the tablet matrix have optimized gel concentrations and porosities to control drug diffusion rates, achieving sustained release without requiring complex multi-layer or multi-component formulations, thus managing manufacturing complexity.
Solution Approach 2:
The patent employs composite materials by combining IMM-H014 drug substance with hydrophilic gel skeleton materials (such as carbomers, chitosan, or gelatin) and fillers in a unified matrix tablet. This composite approach integrates multiple functions (structural support, drug diffusion control, and gastrointestinal stability) into a single formulation system, simplifying manufacturing compared to multi-component systems while achieving sustained release and reduced dosing frequency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sustained-release tablets demonstrate a significant reduction in peak drug concentration and an increase in the time the drug remains in the body, improving patient compliance and reducing side effects.
Implementation Method 1
hydrophilic gel skeleton materials like hydroxypropyl methylcellulose
Implementation Method 2
controlled release and prolonged therapeutic effects
Data Source
AI summary
Provided are an IMM-H014 sustained-release tablet for treating non-alcoholic fatty liver disease, hepatitis and drug-induced liver disease, and a preparation method therefor. The sustained-release tablet is prepared from an active pharmaceutical ingredient IMM-H014 or a pharmaceutically acceptable salt thereof, a framework material, a diluent, a glidant and a lubricant.